Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) (7).”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [7]
In the citing paper
“Familial cancer syndromes caused by fumarate hydratase (FH) or succinate dehydrogenase (SDH) deletion suggest that these TCA enzymes can behave as classical tumor suppressors.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tomlinson et al., 2002
In the citing paper
“Similarly, germline mutations in the broadly expressed enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma, a familial syndrome of uterine and cutaneous leiomyomas and kidney cancer, without susceptibility to more common tumors (11).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [11]
In the citing paper
“In 2001, mutation of fumarate hydratase leading to its inactivation was discovered in renal cell cancer129. Mutation of this enzyme leads to fumarate accumulation not only in skin cancer and uterine leiomyomas but also in breast, bladder, and Leydig cell tumors130.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [130]
In the citing paper
“Consistently, heterozygous germline mutations in genes encoding the TCA cycle enzymes involved in the breakdown of these metabolites—SDH and FH—have been shown to facilitate the pathogenesis of certain rare cancers (e.g., paragangliomas) and inherited cancer-predisposition syndromes (181, 182, 183).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [183]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon.
Liochev, S. I., & Fridovich, I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5892 · Cited by 239
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 213 · cited 1×
“, individuals with von Hippel–Lindau syndrome are predisposed to both phaeochromocytomas and renal carcinoma”
BackgroundKiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
Familial predisposition to uterine leiomyomas
Vikhliaeva, E. M., Сагдуллаевна, Х. З., & Nd, F. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02533-i · Cited by 152 · cited 1×
“gif" NDATA ITEM> ]> Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesi”
Background
Cited by
Items 101–200 of 1,000
Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms
Sotgia, F., Martinez-Outschoorn, U. E., Howell, A., Pestell, R. G., Pavlides, S., & Lisanti, M. P. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-120856 · Cited by 281
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Shidara, Y., Yamagata, K., Kanamori, T., Nakano, K., Kwong, J. Q., Manfredi, G., Oda, H., & Ohta, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2012 · Cited by 286
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
“, 2015), FH (MIM 136850) (Tomlinson et al., 2002), FLCN (MIM 607273) (Schmidt, 2004), MET (MIM 164860) (Schmidt et al.”
SCINA: A Semi-Supervised Subtyping Algorithm of Single Cells and Bulk Samples
Zhang, Z., Luo, D., Zhong, X., Choi, J. H., Ma, Y., Wang, S., Mahrt, E., Guo, W., Stawiski, E. W., Modrusan, Z., et al. (2019) · Genes · doi:10.3390/genes10070531 · Cited by 287
“One minor but aggressive subtype of RCC has been recently identified: hereditary leiomyomatosis and renal cell cancer (HLRCC), which bears morphological similarities to high-grade pRCC and is characterized by germline mutations of the Fumarate Hydratase ( FH ) gene [37].”
BackgroundSDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Bayley, J.-P., Kunst, H. P., Cascon, A., Sampietro, M. L., Gaal, J., Korpershoek, E., Hinojar-Gutierrez, A., Timmers, H. J., Hoefsloot, L. H., Hermsen, M. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70007-3 · Cited by 276
Grubb, R. L., Franks, M. E., Toro, J., Middelton, L., Choyke, L., Fowler, S., Torres-Cabala, C., Glenn, G. M., Choyke, P., Merino, M. J., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.01.155 · Cited by 282
Contemporary Epidemiology of Renal Cell Cancer
Chow, W.-H., & Devesa, S. S. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e3181867628 · Cited by 281
Chen, Y.-B., Brannon, A. R., Toubaji, A., Dudas, M. E., Won, H. H., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Frizzell, N., Voss, M. H., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000163 · Cited by 276
Bardella, C., El‐Bahrawy, M., Frizzell, N., Adam, J., Ternette, N., Hatipoglu, E., Howarth, K., O'Flaherty, L., Roberts, I., Turner, G., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2932 · Cited by 281
Self-citationFumarate induces redox-dependent senescence by modifying glutathione metabolism
Zheng, L., Cardaci, S., Jerby, L., MacKenzie, E. D., Sciacovelli, M., Johnson, T. I., Gaude, E., King, A., Leach, J. D. G., Edrada-Ebel, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms7001 · Cited by 281
“The biallelic inactivation of FH leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC), a hereditary cancer syndrome characterized by the presence of benign tumours of the skin and uterus and a highly malignant form of renal cell cancer 1 .”
Revisiting the TCA cycle: signaling to tumor formation
Raimundo, N., Baysal, B. E., & Shadel, G. S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.001 · Cited by 271
“Kiuru M, Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC).”
BackgroundInfluentiall -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer
Shim, E.-H., Livi, C. B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.-Y., Ghosh, A. P., Kirkman, R., Velu, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0696 · Cited by 280
The NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascon, A., Benn, D. E., Bayley, J.-P., Welander, J., Tops, C. M., Firth, H., Dwight, T., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 275
Mitochondria in cancer: Not just innocent bystanders
Frezza, C., & Gottlieb, E. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.008 · Cited by 268
“An important link between metabolism and cancer was added n the present decade demonstrating that the nuclear encoded TCA ycle enzymes SDH and FH are tumour suppressors [5,6].”
BackgroundProteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress
van der Reest, J., Lilla, S., Zheng, L., Zanivan, S., & Gottlieb, E. (2018) · Nature Communications · doi:10.1038/s41467-018-04003-3 · Cited by 270
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Defects in mitochondrial metabolism and cancer
Gaude, E., & Frezza, C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-10 · Cited by 251
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. A. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 250
“FH Renal cell carcinoma [163] and paragangliom”
Trpkov, K., Hes, O., Agaimy, A., Bonert, M., Martinek, P., Magi-Galluzzi, C., Kristiansen, G., Lüders, C., Nesi, G., Compérat, E., et al. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000617 · Cited by 255
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.02.004 · Cited by 258
Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses
Choi, I., Son, H., & Baek, J.-H. (2021) · Life · doi:10.3390/life11010069 · Cited by 241
“Brennan, M.S.; Matos, M.F.; Li, B.; Hronowski, X.; Gao, B.; Juhasz, P.; Rhodes, K.J.; Scannevin, R.H. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.”
BackgroundInfluentialShroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507228112 · Cited by 255
Molecular genetics and clinical features of Birt–Hogg–Dubé syndrome
Schmidt, L. S., & Linehan, W. M. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.206 · Cited by 255
Genetic Basis of Cancer of the Kidney
Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050013 · Cited by 251
2009 update on the classification of renal epithelial tumors in adults
Lopez‐Beltran, A., Carrasco, J. C., Cheng, L., Scarpelli, M., Kirkali, Z., & Montironi, R. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02302.x · Cited by 243
Mitochondrial dysfunction in neurodegenerative diseases and cancer
de Moura, M. B., dos Santos, L. S., & Van Houten, B. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20575 · Cited by 243
Lucarelli, G., Loizzo, D., Franzin, R., Battaglia, S., Ferro, M., Cantiello, F., Castellano, G., Bettocchi, C., Ditonno, P., & Battaglia, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1607729 · Cited by 244
“subunits B, C, and D of succinate dehydrogenase (SDHB/ SDHC/SDHD) [13,14] were identified in patients with familial”
BackgroundPKM2, a Central Point of Regulation in Cancer Metabolism
Wong, N., De Melo, J., & Tang, D. (2013) · International Journal of Cell Biology · doi:10.1155/2013/242513 · Cited by 243
TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer
Hua, W., ten Dijke, P., Kostidis, S., Giera, M., & Hornsveld, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03398-6 · Cited by 238
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
“HLRCC gene: Fumarate hydratase—the Warburg effect The gene for HLRCC encodes the Krebs cycle enzyme, fumarate hydratase (FH) (Tomlinson et al. 2002).”
BackgroundGlutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 235
Choyke, P. L., Glenn, G. M., Walther, M. M., Zbar, B., & Linehan, W. M. (2003) · Radiology · doi:10.1148/radiol.2261011296 · Cited by 246
Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer
Ricketts, C. J., Shuch, B., Vocke, C. D., Metwalli, A. R., Bratslavsky, G., Middelton, L., Yang, Y., Wei, M.-H., Pautler, S. E., Peterson, J., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.08.030 · Cited by 240
High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dubé–Associated Renal Tumors
Vocke, C. D., Yang, Y., Pavlovich, C. P., Schmidt, L. S., Nickerson, M. L., Torres-Cabala, C. A., Merino, M. J., Walther, M. M., Zbar, B., & Linehan, W. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji154 · Cited by 241
Protein Lysine Acylation and Cysteine Succination by Intermediates of Energy Metabolism
Lin, H., Su, X., & He, B. (2012) · ACS Chemical Biology · doi:10.1021/cb3001793 · Cited by 234
A Molecular Classification of Papillary Renal Cell Carcinoma
Yang, X. J., Tan, M.-H., Kim, H. L., Ditlev, J. A., Betten, M. W., Png, C. E., Kort, E. J., Futami, K., Furge, K. A., Takahashi, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0533 · Cited by 232
“Differential expression of the FH gene, which is mutated in a group of families with type 2 PRCC (38), was not observed (data not shown).”
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 224
“A series of oncometabolites have been identified, including 2hydroxyglutarate and glucose in gliomas and acute myeloid leukemia [226–228], fumarate in papillary kidney cancer [229], succinate in pheochromocytoma [230], sarcosine and choline in Pca [231, 232], glutamine in pancreatic [233, 234], asparagine in ovarian c…”
BackgroundCellular oxygen sensing need in CNS function: physiological and pathological implications
Acker, T., & Acker, H. (2004) · Journal of Experimental Biology · doi:10.1242/jeb.01075 · Cited by 231
“…in the autosomally encoded enzyme and enzyme subunits are associated with hereditary predispositions to various tumors including paraganglioma, pheochromocytoma, benign smooth muscle cell tumor and RCC (Tomlinson et al., 2002; Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001).”
BackgroundMetabolic regulation of chromatin modifications and gene expression
Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233
“For example, loss-of-function mutations in the metabolic enzymes succinate dehydrogenase (SDH; Baysal et al., 2000) and fumarate hydratase (FH; Tomlinson et al., 2002) were originally associated with cancer syndromes including hereditary paraganglioma and pheochromocytomas and hereditary…”
BackgroundXie, H., Valera, V. A., Merino, M. J., Amato, A. M., Signoretti, S., Linehan, W. M., Sukhatme, V. P., & Seth, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1049 · Cited by 233
Increased risk of cancer in patients with fumarate hydratase germline mutation
Lehtonen, H. J., Kiuru, M., Ylisaukko-oja, S. K., Salovaara, R., Herva, R., Koivisto, P. A., Vierimaa, O., Aittomäki, K., Pukkala, E., Launonen, V, et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036400 · Cited by 225
Cancer metabolism in space and time: Beyond the Warburg effect
Danhier, P., Bański, P., Payen, V. L., Grasso, D., Ippolito, L., Sonveaux, P., & Porporato, P. E. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.001 · Cited by 214
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 216
Linehan, W. M., & Rouault, T. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0304 · Cited by 223
Is cancer a disease of abnormal cellular metabolism? New angles on an old idea
Deberardinis, R. J. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31818b0d9b · Cited by 219
Novel approaches in the therapy of metastatic renal cell carcinoma
Lam, J. S., Leppert, J. T., Belldegrun, A. S., & Figlin, R. A. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0466-0 · Cited by 223
“Another new renal-cancerpredisposing gene, HRPT2, was identified through linkage analysis in families with hyperparathyroidismjaw tumor syndrome (HPT-JT) [86].”
BackgroundLandmarks in the diagnosis and treatment of renal cell carcinoma
Bhatt, J. R., & Finelli, A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.194 · Cited by 218
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
“Genes encoding succinate dehydrogenase (SDH) and fumarate hydratase (FH) act as tumour suppressors (Astuti et al. 2001; Baysal et al. 2000; Burnichon et al. 2010; Castro-Vega et al. 2014; Tomlinson et al. 2002).”
BackgroundYogev, O., Yogev, O., Singer, E., Shaulian, E., Goldberg, M., Fox, T. D., & Pines, O. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000328 · Cited by 220
“This syndrome is characterized by benign cutaneous and uterine leiomyomas, renal cell carcinomas, and uterine leiomyosarcomas [13,14].”
Clinical presentation of fibroids
Gupta, S., Jose, J., & Manyonda, I. (2008) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2008.01.008 · Cited by 218
Hereditary Kidney Cancer Syndromes
Haas, N. B., & Nathanson, K. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.10.001 · Cited by 208
Single-Gene Disorders: What Role Could Moonlighting Enzymes Play?
Sriram, G., Martinez, J. A., McCabe, E. R. B., Liao, J. C., & Dipple, K. M. (2005) · The American Journal of Human Genetics · doi:10.1086/430799 · Cited by 213
“Recently, it was discovered that a gene that predisposes to inherited multiple uterine leiomyomata (fibroids) (MIM 150800) and papillary renal cell cancer (MIM 650839) is the same as the gene encoding fumarate hydratase (Tomlinson et al. 2002).”
BackgroundSudarshan, S., Sourbier, C., Kong, H.-S., Block, K., Romero, V. A. V., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00483-09 · Cited by 217
“Genetic analysis of tumor samples indicates that FH acts as a tumor suppressor gene (37).”
BackgroundExploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
Thomas, L. W., & Ashcroft, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03039-y · Cited by 213
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 217
Searching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1364 · Cited by 209
“cgi?id=605839">hereditary leiomyomatosis and renal-cell cancer (HLRCC”
Tong, W.-H., Sourbier, C., Kovtunovych, G., Jeong, S. Y., Vira, M., Ghosh, M., Romero, V. V., Sougrat, R., Vaulont, S., Viollet, B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.018 · Cited by 212
“…a key role in energy production as well as biosynthesis of lipid and amino acids, and mutations of the TCA cycle genes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), are associated with tumor formation (Baysal et al., 2000; King et al., 2006; Tomlinson et al., 2002; Toro et al., 2003).”
Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment
Martucci, V. L., & Pacak, K. (2014) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2014.01.001 · Cited by 204
van Gisbergen, M. W., Voets, A. M., Starmans, M. H. W., de Coo, I. F. M., Yadak, R., Hoffmann, R. F., Boutros, P. C., Smeets, H. J. M., Dubois, L., & Lambin, P. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2015.01.001 · Cited by 203
“For other cancers like uterine leiomyomas and RCCs [46,47], associations with mutations were found in other nuclear-encoded mitochondrial genes such as fumarate hydratase.”
Genomics of uterine leiomyomas: insights from high-throughput sequencing
Mehine, M., Mäkinen, N., Heinonen, H.-R., Aaltonen, L. A., & Vahteristo, P. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.06.050 · Cited by 200
Pugh, C. W., & Ratcliffe, P. J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00103-7 · Cited by 201
Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene
Cascón, A., Comino-Méndez, I., Currás-Freixes, M., de Cubas, A. A., Contreras, L., Richter, S., Peitzsch, M., Mancikova, V., Inglada-Pérez, L., Pérez-Barrios, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv053 · Cited by 192
Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1
Na, H.-K., & Surh, Y.-J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.10.819 · Cited by 202
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma
Buffet, A., Burnichon, N., Favier, J., & Gimenez-Roqueplo, A.-P. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101416 · Cited by 189
Clinical Features of Multiple Cutaneous and Uterine Leiomyomatosis: An Underdiagnosed Tumor Syndrome
Alam, N. A., Barclay, E., Rowan, A. J., Tyrer, J. P., Calonje, E., Manek, S., Kelsell, D., Leigh, I., Olpin, S., & Tomlinson, I. P. M. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.2.199 · Cited by 197
“Diagnosis After biopsy by a dermatologist 33/54 (61) After biopsy by a general practitioner 4/54 (7) By us during this study 17/54 (32) Nonprobands by us during this study 17/24 (71) CLM treatment None 48/65 (74) Surgery 10/65 (15) Laser 3/65 (5) Surgery and laser 2/65 (3) Medication 2/65 (3)”
BackgroundSmit, D., Mensenkamp, A., Badeloe, S., Breuning, M., Simon, M., Van Spaendonck, K., Aalfs, C., Post, J., Shanley, S., Krapels, I., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01486.x · Cited by 195
Sarcoma Epidemiology and Etiology: Potential Environmental and Genetic Factors
Lahat, G., Lazar, A., & Lev, D. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.03.006 · Cited by 194
Intermediates of Metabolism: From Bystanders to Signalling Molecules
Haas, R., Cucchi, D., Smith, J., Pucino, V., Macdougall, C. E., & Mauro, C. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.02.003 · Cited by 193
“Fumarate has been recently defined as a proto-oncometabolite [40,41] because its accumulation, due to loss-of-function mutations in fumarate hydratase (FH) [42,43], results in stabilisation of Hif-1/ via two different mechanisms: the inhibition of prolyl hydroxylase domain-containing protein 2”
BackgroundLingaas, F. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg336 · Cited by 192
“Mutations in the gene encoding fumarate hydratase (FH) cause a predisposion to uterine leiomyomas, benign tumors of the skin and papillary renal cell carcinoma, a phenotype that is quite similar to RCND (28,29).”
BackgroundOxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
Chen, Y., Cairns, R., Papandreou, I., Koong, A., & Denko, N. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007033 · Cited by 187
“Through genetic studies, fumarate hydrolase and succinate dehydrogenase have been shown to be tumor suppressors [19,20].”
BackgroundArslan, A. A., Gold, L. I., Mittal, K., Suen, T.-C., Belitskaya-Levy, I., Tang, M.-S., & Toniolo, P. (2005) · Human Reproduction · doi:10.1093/humrep/deh698 · Cited by 195
“Recently, reports of several families in Finland and England with multiple uterine and cutaneous fibroids, and papillary renal cell carcinoma, were linked to mutations in the fumarate hydratase gene (Tomlinson et al., 2002).”
BackgroundCommandeur, A. E., Styer, A. K., & Teixeira, J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv030 · Cited by 186
You, Y.-H., Quach, T., Saito, R., Pham, J., & Sharma, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030302 · Cited by 192
Analysis of omics data with genome-scale models of metabolism
Hyduke, D. R., Lewis, N. E., & Palsson, B. Ø. (2012) · Molecular BioSystems · doi:10.1039/c2mb25453k · Cited by 179
The emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Sutendra, G., Dromparis, P., Kinnaird, A., Stenson, T. H., Haromy, A., Parker, J. M. R., McMurtry, M. S., & Michelakis, E. D. (2013) · Oncogene · doi:10.1038/onc.2012.198 · Cited by 184
Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
Klatte, T., Pantuck, A. J., Said, J. W., Seligson, D. B., Rao, N. P., LaRochelle, J. C., Shuch, B., Zisman, A., Kabbinavar, F. F., & Belldegrun, A. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1229 · Cited by 186
“cancer is caused by a mutation of the fumarate hydratase gene , leading to cutaneous and uterine leiomyomas and an aggressive type 2 PRCC (7, 8).”
BackgroundModeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 183
“Soon after this seminal discovery, fumarate hydratase (FH), the enzyme that converts fumarate to malate, was found mutated in hereditary leiomyomatosis and renal cell cancer (HLRCC) (Kiuru et al , 2002; Tomlinson et al , 2002).”
BackgroundLehtonen, R., Kiuru, M., Vanharanta, S., Sjöberg, J., Aaltonen, L.-M., Aittomäki, K., Arola, J., Butzow, R., Eng, C., Husgafvel-Pursiainen, K., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63091-x · Cited by 181
“In these families, affected individuals typically develop leiomyomas of the skin and/or uterus.(1,2) In addition to leiomyomas, some families are also predisposed to papillary renal cell carcinoma and uterine leiomyosarcoma.”
BackgroundResultInfluentialOncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
“Whilst homozygous FH mutations cause fumaric aciduria, a condition associated with infantile encephalopathy and brain malformations [39], heterozygous FH mutations followed by the loss of heterozygosity of the second allele cause Hereditary Leio-myomatosis and Renal Cell Cancer (HLRCC) [13,40].”
BackgroundPollard, P. J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.005 · Cited by 178
Cheng, J., Yan, J., Liu, Y., Shi, J., Wang, H., Zhou, H., Zhou, Y., Zhang, T., Zhao, L., Meng, X., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.04.017 · Cited by 177
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
“Mutations in the TCA cycle enzymes succinate dehydrogenase (SDH)[42, 43] and fumarate hydratase (FH)[44] lead to familial cancer syndromes such as paraganglioma, ACCEPTED MANUSCRIPT”
Loss of Complex I due to Mitochondrial DNA Mutations in Renal Oncocytoma
Mayr, J. A., Meierhofer, D., Zimmermann, F., Feichtinger, R., Kögler, C., Ratschek, M., Schmeller, N., Sperl, W., & Kofler, B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4131 · Cited by 174
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma
Bertsch, E., Qiang, W., Zhang, Q., Espona-Fiedler, M., Druschitz, S., Liu, Y., Mittal, K., Kong, B., Kurita, T., & Wei, J.-J. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.243 · Cited by 172
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism
Dai, W., Xu, L., Yu, X., Zhang, G., Guo, H., Liu, H., Song, G., Weng, S., Dong, L., Zhu, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.015 · Cited by 174
Metabolic changes in cancer: beyond the Warburg effect
Wu, W., & Zhao, S. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms104 · Cited by 173
McGuire, M. M., Yatsenko, A., Hoffner, L., Jones, M., Surti, U., & Rajkovic, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033251 · Cited by 170
“Rare hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC [MIM 150800]) is caused by heterozygous germline mutations in the gene encoding fumarate hydratase, but the role(s) of individual genes in common leiomyomas is not well understood [10,11].”
BackgroundThe Yeast Mitochondrial Proteome, a Study of Fermentative and Respiratory Growth
Ohlmeier, S., Kastaniotis, A. J., Hiltunen, J. K., & Bergmann, U. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310160200 · Cited by 174
Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion
Kreuzaler, P., Panina, Y., Segal, J., & Yuneva, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.021 · Cited by 163
“Furthermore, stabilization of HIF by competitive inhibition of PHD through accumulation of fumarate in FH mutant tumors is associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), although it is unclear if this is a bystander effect or a requirement [97,98].”
BackgroundTCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 161
Bayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
“In 2002, the Multiple Leiomyoma Consortium identified FH as the tumor suppressor gene responsible for MCUL/HLRCC [3].”
BackgroundInfluentialMolecular Diagnosis and Therapy of Kidney Cancer
Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S., Neckers, L., Bottaro, D. P., & Srinivasan, R. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042808.171650 · Cited by 167
“Targeting the fumarate hydratase gene in type 2 papillary kidney cancer—The Krebs cycle enzyme, fumarate hydratase, is the gene for HLRCC.(78) Mutations of the fumarate hydratase gene are found in over 90% of HLRCC families.”
BackgroundFumarate hydratase in cancer: A multifaceted tumour suppressor
Schmidt, C., Sciacovelli, M., & Frezza, C. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.002 · Cited by 160
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 162
“Heterozygous germline FH mutations cause hereditary leiomyomatosis and renal cell cancer (HLRCC), a syndrome characterized by cutaneous and uterine leiomyomas as well as RCC [3, 129].”
BackgroundLin, C.-C., Cheng, T.-L., Tsai, W.-H., Tsai, H.-J., Hu, K.-H., Chang, H.-C., Yeh, C.-W., Chen, Y.-C., Liao, C.-C., & Chang, W.-T. (2012) · Scientific Reports · doi:10.1038/srep00785 · Cited by 155
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 160
“The FH gene acts as a tumor suppressor based on the identification of LOH or “second hit” somatic mutations in the wild-type FH allele in syndromic uterine and cutaneous leiomyomas [63,64,66] and HLRCC-associated renal tumors [66,68].”
BackgroundOncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
“predispose to HLRCC syndrome, which involves cutaneous and uterine leiomyomas and kidney cancers.(13) We recently”
BackgroundHereditary renal cell carcinoma syndromes: diagnosis, surveillance and management
Maher, E. R. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2288-5 · Cited by 182
Metadata
- Authors
- The Multiple Leiomyoma Consortium
- Venue
- Nature Genetics
- Published
- 2002-02-25
- Volume
- 30
- Issue
- 4
- Pages
- 406-410
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1967291345
- Cited by
- 1,635
- References
- 17
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 57 · 2022: 65 · 2021: 80 · 2020: 93 · 2019: 86 · 2018: 81 · 2017: 90 · 2016: 106 · 2015: 89 · 2014: 85 · 2013: 82 · 2012: 82
- FWCI
- 56.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.S. Public Health Service (U59309)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fumarate hydratase, FH gene, germline mutations, uterine fibroids, cutaneous leiomyoma, papillary renal cell carcinoma, cancer susceptibility, tumor suppressor, fumarate hydratase deficiency, compound heterozygosity, TCA cycle, fibroid pathogenesis
- MeSH terms
- Alleles, Carcinoma, Papillary, Carcinoma, Renal Cell, Chromosomes, Human, Pair 1, Exons, Female, Fumarate Hydratase, Genes, Dominant, Genetic Markers, Humans, Kidney Neoplasms, Leiomyoma, Male, Mutation, Pedigree, Recombination, Genetic, Uterine Neoplasms, Gene Deletion, In Situ Hybridization, Fluorescence, Sequence Analysis, DNA, Germ-Line Mutation, Leiomyoma, Epithelioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.